Introduction
Early detection of pancreatic cancer could save many thousands of lives. Non-invasive diagnostic imaging, including PET with [18F]FDG, have inadequate resolution for detection of small (2–3 mm) pancreatic tumors. We demonstrated the efficacy of PET imaging with an 18F-labeled lactose derivative, [18F]FEDL, that targets HIP/PAP, a biomarker that is overexpressed in the peritumoral pancreas. We developed another analogue, 1-[18F]fluoroethyl lactose ([18F]FEL), which is simpler to synthesize, for the same application. We conducted a preliminary evaluation of the new probe and its efficacy in detecting orthotopic pancreatic carcinoma xenografts in mice.
Methods
Xenografts were developed in nude mice by injecting L3.6pl/GL+ pancreatic carcinoma cells into the pancreas of each mouse. Tumor growth was monitored by bioluminescence imaging (BLI); accuracy of BLI tumor size estimates was verified by MRI in two representative mice. When the tumor size reached approximately 2–3 mm, the animals were injected with [18F]FEL (3.7 MBq) and underwent static PET/CT scans. Blood samples were collected at 2, 5, 10, 20 and 60 min after [18F]FEL injection to track blood clearance. Following imaging, animals were sacrificed and their organs and tumors/pancreatic tissue were collected and counted on a gamma counter. Pancreas, including tumor, was frozen, sliced and used for autoradiography and immunohistochemical analysis of HIP/PAP expression.
Results
Tumor growth was rapid, as observed by BLI and MRI. Blood clearance of [18F]FEL was bi-exponential, with half-lives of approximately 3.5 min and 40 min. Mean accumulation of [18F]FEL in the peritumoral pancreatic tissue was 1.29±0.295 %ID/g, and that in the normal pancreas of control animals was 0.090±0.101 %ID/g. [18F]FEL was cleared predominantly by the kidneys. Comparative analysis of autoradiographic images and immunostaining results demonstrated a correlation between [18F]FEL binding and HIP/PAP expression.
Conclusion
[18F]FEL may be useful for non-invasive imaging of early-stage pancreatic tumors by PET. The results warrant further studies.